SUBSCRIBE
SUBSCRIBE
News   Drug Development

Aradigm Corporation Files Request For Orphan Drug Designation For Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis

January 6, 2006 | 
1 min read
Aradigm Corporation (NASDAQ: ARDMD) today announced that it has filed a request for orphan drug designation with the United States Food and Drug Administration (FDA) for its liposomal ciprofloxacin product for the management of cystic fibrosis (CF).
Clinical research Phase 1
MORE ON THIS TOPIC
Orlando, Florida
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
March 31, 2026
 · 
4 min read
 · 
Tristan Manalac
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Immunology and inflammation
Viridian Turns Red as Thyroid Eye Disease Data Disappoint
March 31, 2026
 · 
2 min read
 · 
Tristan Manalac
ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
March 31, 2026
 · 
2 min read
 · 
Tristan Manalac
Yellow diagram of pulses on a stack of red paper hearts. Illustration of the concept of healthy lifestyles and cardiovascular related diseases
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
March 30, 2026
 · 
2 min read
 · 
Annalee Armstrong